Literature DB >> 1283363

Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer's disease: a postmortem study.

A J Nazarali1, G P Reynolds.   

Abstract

1. Concentrations of the neurotransmitter amines noradrenaline (NA), dopamine (DA), and 5-hydroxytryptamine (5-HT) and the acid metabolites homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) were determined in four regions of postmortem brains of demented patients with or without Alzheimer's disease (AD). 2. NA was deficient in the temporal cortex (BA 21) of AD, but not of non-AD, patients. 3. Caudate, in particular, had an impaired dopaminergic system in AD patients, with low HVA levels. 4. In all regions investigated [amygdala, caudate, putamen, temporal cortex (BA 21)] 5-HT was significantly depleted in AD patients, and 5-HIAA was also depleted in amygdala and caudate. 5. These results indicate that neurotransmitter systems other than cholinergic systems are also widely affected in AD and suggest that these deficits may also play an important role in determining the symptomatology of AD.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1283363     DOI: 10.1007/BF00711237

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  29 in total

1.  Letter: Mental changes in Parkinsonism.

Authors:  J Pearce
Journal:  Br Med J       Date:  1974-05-25

2.  Neurotransmitters and CNS disease. Dementia.

Authors:  M N Rossor
Journal:  Lancet       Date:  1982-11-27       Impact factor: 79.321

Review 3.  Non-cholinergic neurotransmitter abnormalities in Alzheimer's disease.

Authors:  M Rossor; L L Iversen
Journal:  Br Med Bull       Date:  1986-01       Impact factor: 4.291

4.  Selective vulnerability of neurones in organic dementia.

Authors:  J A Spillane; P White; W J Goodhardt; R H Flack; D M Bowen; A N Davison
Journal:  Nature       Date:  1977-04-07       Impact factor: 49.962

5.  Selective loss of central cholinergic neurons in Alzheimer's disease.

Authors:  P Davies; A J Maloney
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

6.  Necropsy evidence of central cholinergic deficits in senile dementia.

Authors:  E K Perry; R H Perry; G Blessed; B E Tomlinson
Journal:  Lancet       Date:  1977-01-22       Impact factor: 79.321

7.  Reduced dopamine-beta-hydroxylase activity in Alzheimer's disease.

Authors:  A J Cross; T J Crow; E K Perry; R H Perry; G Blessed; B E Tomlinson
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-10

8.  Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis.

Authors:  P J Whitehouse; D L Price; A W Clark; J T Coyle; M R DeLong
Journal:  Ann Neurol       Date:  1981-08       Impact factor: 10.422

9.  Changes in the monoamine containing neurones of the human CNS in senile dementia.

Authors:  D M Mann; J Lincoln; P O Yates; J E Stamp; S Toper
Journal:  Br J Psychiatry       Date:  1980-06       Impact factor: 9.319

10.  Neurotransmitter and receptor deficits in senile dementia of the Alzheimer type.

Authors:  R Quirion; J C Martel; Y Robitaille; P Etienne; P Wood; N P Nair; S Gauthier
Journal:  Can J Neurol Sci       Date:  1986-11       Impact factor: 2.104

View more
  21 in total

Review 1.  Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease.

Authors:  Kentaro Hirao; Gregory M Pontone; Gwenn S Smith
Journal:  Neurosci Biobehav Rev       Date:  2014-11-20       Impact factor: 8.989

2.  Association between serotonin denervation and resting-state functional connectivity in mild cognitive impairment.

Authors:  Frederick S Barrett; Clifford I Workman; Haris I Sair; Alena V Savonenko; Michael A Kraut; Devin J Sodums; Jin J Joo; Najlla Nassery; Christopher M Marano; Cynthia A Munro; Jason Brandt; Yun Zhou; Dean F Wong; Gwenn S Smith
Journal:  Hum Brain Mapp       Date:  2017-04-05       Impact factor: 5.038

3.  Molecular imaging of serotonin degeneration in mild cognitive impairment.

Authors:  Gwenn S Smith; Frederick S Barrett; Jin Hui Joo; Najlla Nassery; Alena Savonenko; Devin J Sodums; Christopher M Marano; Cynthia A Munro; Jason Brandt; Michael A Kraut; Yun Zhou; Dean F Wong; Clifford I Workman
Journal:  Neurobiol Dis       Date:  2017-05-13       Impact factor: 5.996

Review 4.  Serotonergic therapies for cognitive symptoms in Alzheimer's disease: rationale and current status.

Authors:  Maria J Ramirez; Mitchell K P Lai; Rosa M Tordera; Paul T Francis
Journal:  Drugs       Date:  2014-05       Impact factor: 9.546

Review 5.  Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons.

Authors:  Ravi Rajmohan; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

6.  Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease.

Authors:  Marwa Aboukhatwa; Laura Dosanjh; Yuan Luo
Journal:  Mol Neurodegener       Date:  2010-03-12       Impact factor: 14.195

Review 7.  Why pleiotropic interventions are needed for Alzheimer's disease.

Authors:  Sally A Frautschy; Greg M Cole
Journal:  Mol Neurobiol       Date:  2010-05-02       Impact factor: 5.590

8.  Ablation of the locus coeruleus increases oxidative stress in tg-2576 transgenic but not wild-type mice.

Authors:  Orest Hurko; Kurt Boudonck; Cathleen Gonzales; Zoe A Hughes; J Steve Jacobsen; Peter H Reinhart; Daniel Crowther
Journal:  Int J Alzheimers Dis       Date:  2010-10-11

9.  Effect of Zhuang Jing Decoction on Learning and Memory Ability in Aging Rats.

Authors:  Hao-Bin Cai; Guang-Liang Wu; Cen-Han Huang; Zhong-Shi Huang; Yun-Bo Chen; Qi Wang
Journal:  Rejuvenation Res       Date:  2016-02-23       Impact factor: 4.663

10.  Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease.

Authors:  Gwenn S Smith; Elisse Kramer; Yilong Ma; Carol R Hermann; Vijay Dhawan; Thomas Chaly; David Eidelberg
Journal:  Brain       Date:  2009-01-19       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.